
Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP) shares are trading higher Wednesday after the company announced that the United States Patent and Trademark Office issued a patent to Tonix titled, "Synthetic Chimeric Poxviruses."
The patent includes claims covering synthetic horsepox virus, the basis for the company's TNX-8011 vaccine in development to protect against monkeypox and smallpox and for the company's Recombinant Pox Virus platform to protect against other pathogens, including SARS-CoV-2.